Press Resease

Active Pharmaceutical Ingredients Market - Global Industry Analysis

Active Pharmaceutical Ingredients Market By API Synthesis Segment Analysis (Biotech API, Synthetic Chemical API, HPAPI), By Type of Manufacturing Segment Analysis (Contract Manufacturing, In-House API Manufacturing), By Type of API Segment Analysis (Synthetic API, Biological API), By Drug Type Segment Analysis (Branded Drugs, Generic Drugs, OTC Drugs), By Therapeutic Application Segment Analysis (Cardiology, Oncology, Anti-Inflammatory, Gastrointestinal, Other) : Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2028

Published Date: 12-Jun-2021 Category: Pharmaceutical Report Format : PDF Pages: 120 Report Code: ZMR-56 Status : Published

Global Active Pharmaceutical Ingredients Market accounted for USD 202.90 Billion in 2020 and is expected to reach USD 101.48 Billion by 2028, growing at a CAGR of 5.1% from 2021 to 2028.

Description

Market Overview

Global Active Pharmaceutical Ingredients Market accounted for USD 202.90 Billion in 2020 and is expected to reach USD 101.48 Billion by 2028, growing at a CAGR of 5.1% from 2021 to 2028.

Active Pharmaceutical Ingredient means the active ingredient which is contained in every medicine. For example, an active ingredient to relieve pain is included in a painkiller. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Due to the advancements in active pharmaceutical ingredient manufacturing and the increasing prevalence of chronic diseases, such as cardiovascular diseases and cancer obesity, osteoporosis, and pulmonary diseases, it has proved favorable market conditions in the active pharmaceutical ingredients market.

Holding a largely geriatric population and growing concerns of increasing chronic disorders have proved to be beneficial for the market growth. Increasing healthcare importance and infected incidences has caused measurable growth under active pharmaceutical ingredients market. Owing to the rising drug research and development activities for manufacturing, the rising importance of generics have together enhanced the market size for the active pharmaceutical ingredients market. The unfavorable drug price control policies across various nations and high manufacturing costs are expected to weaken the growth of the market.
 

COVID-19 Impact Analysis

Due to the deadly discovery of COVID-19, it had a favourable impact on the market as the countries and major manufacturing players huge amounts of ingredients to maintain the demand for the treatment of COVID 19. This has caused the drug manufacturers to redirect their focus and energy on a larger pool of patients. On the other hand, cross countries trade has become questionable and uncertain causing it to be a hindrance in the post pandemic world. Furthermore, governments of many countries have formulated plans and granted incentives to promote and support the production of API.

Due to the outbreak of the pandemic, the entire world was forced to go on a shutdown, causing factors like the shortage of labour and raw materials, and therefore ending in several problems in the manufacture of the equipment. Therefore, there is an underlying impact on the revenue of market-players, and created a huge gap in demand-supply chain.

Growth Factors

Some of the factors driving the growth of active pharmaceutical ingredients market is the increasing prevalence of chronic disorders care and support, older population, high investment in the department of research and development, increased spending on the healthcare, growing incidence of COVID-19 cases, and the inevitable technological advancements. In the recent past, the incidence of chronic diseases such as diabetes, coronary artery disease, chronic obstructive pulmonary disease (COPD), asthma, hepatitis, arthritis, and cancer has increased significantly in major regions across the globe. This can be attributed to the rising geriatric population across the globe, changing lifestyles, and dietary changes as a result of rapid urbanization.

Hence, there is an impulsive need for the active pharmaceutical ingredients in the pandemic-stricken world of today. The anticipated growth in the market is promising for the forecasted period.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

 

Drug Type Segment Analysis Preview

On the basis of type of drug, the active pharmaceutical ingredients market is segmented into branded drugs, general drugs and over-the-counter drugs. As per latest study, branded drugs segment is dominating the active pharmaceutical ingredients market because of high cost of the drugs which will increase the APIs and manufacturing cost of the APIs.

Due to the rising cost of healthcare, governments and investors are pushing for increasing generics consumption over branded drugs, thus driving the growth of generic APIs market, in the predicted period. Additionally, several major pharmaceutical companies are also focusing on generic drugs along with branded drugs due to valid reasons like eroding product pipeline and patent expirations.

API Synthesis Segment Analysis Preview

The synthetic API segment holds a dominance due to the higher availability of raw materials and easier protocols for the synthesis of these molecules. Many synthetic molecules are also anticipated to go off-patent in the coming years, which indirectly caters to the growth.

The biotech segment is expected to expand over the forecast period, driven by factors such as increasing demand for biopharmaceuticals and higher efficiency of these molecules. Furthermore, the growth of the biotech segment can be attributed to high investments in the biotechnology sectors. This allows the innovation of new molecules that aid in the treatment of diseases, such as cancer.

Therapeutic Application Type Segment Analysis Preview

On the basis of therapeutic application, the market is bifurcated into Cardiology, Oncology, Anti-Inflammatory, Gastrointestinal, Others. The cardiology diseases segment accounts to be the largely beneficial, attributed to the increasing prevalence of target diseases worldwide. Various organizations such as the World Heart Federation, the World Stroke Organization are working toward increasing awareness about cardiology diseases.

Many government initiatives programs are aimed at improving awareness related to cholesterol-related diseases. Increasing awareness about cardiology diseases and high prevalence are anticipated to drive the segment over the forecast period, thus driving demand for APIs for cardiology drugs. Although, oncology is expected to be the fastest-growing application segment with due consideration to factors such as changing lifestyles and the growing prevalence of cancer.

Regional Analysis Preview

Geographically, the active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and Rest of the World. In recent times, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia Pacific. The reason for North America’s dominance in the global market is attributed to the rising incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for specialty drugs, and technological advancements in the manufacturing processes of APIs.

During the forecasted period, Asia Pacific is anticipated to have an accelerated growth. The presence of economies like China and India among the Asia Pacific, which the world relies on for low-cost API production, is a benefit for the region. The market is expected to rise due to rising healthcare expenditure in the region.

Key Market Players & Competitive Landscape

Some of the leading players in the market are Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Cipla, Inc., Teva Pharmaceutical Industries Ltd., Albemarle Corporation, Viatris Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd.

The global home Active pharmaceutical ingredients market is segmented as follows:

By Synthesis Segment Analysis:

  • Biotech API
  • Synthetic Chemical API
  • HPAPI

By Manufacturing Type Segment Analysis:

  • Contract Manufacturing
  • In-House API Manufacturing

By API Type Segment Analysis:

  • Synthetic API
  • Biological API

By Drug Type Segment Analysis:

  • Branded Drugs
  • Generic Drugs
  • OTC Drugs

By Therapeutic Application Segment Analysis:

  • Cardiology
  • Oncology
  • Anti-Inflammatory
  • Gastrointestinal
  • Other

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Synthesis
        • 2.1.1.2. Market Attractiveness Analysis, By Manufacturing Type
        • 2.1.1.3. Market Attractiveness Analysis, By API Type
        • 2.1.1.4. Market Attractiveness Analysis, By Drug Type
        • 2.1.1.5. Market Attractiveness Analysis, By Therapeutic Application
        • 2.1.1.4. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Active Pharmaceutical Ingredients Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Active Pharmaceutical Ingredients Market – Synthesis Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Synthesis, 2020 & 2028
    • 4.2. Biotech API
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Synthetic Chemical API
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. HPAPI
      • 4.4.1. Market Size and Forecast, By Region (USD Billion)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Active Pharmaceutical Ingredients Market – Manufacturing Type Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Manufacturing Type, 2020 & 2028
    • 5.2. Contract Manufacturing
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. In-House API Manufacturing
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Active Pharmaceutical Ingredients Market – API Type Segment Analysis
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By API Type, 2020 & 2028
    • 6.2. Synthetic API
      • 6.2.1. Market Size and Forecast, By Region (USD Billion)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Biulogical API
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Active Pharmaceutical Ingredients Market – Drug Type Segment Analysis
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By Drug Type, 2020 & 2028
    • 6.2. Branded Drugs
      • 6.2.1. Market Size and Forecast, By Region (USD Billion)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Generic Drugs
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. OTC Drugs
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Active Pharmaceutical Ingredients Market – Therapeutic Application Segment Analysis
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By Therapeutic Application, 2020 & 2028
    • 6.2. Cardiulogy
      • 6.2.1. Market Size and Forecast, By Region (USD Billion)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Onculogy
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Anti-inflammatory
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Gastrointestinal
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Other
      • 6.3.1. Market Size and Forecast, By Region (USD Billion)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 7 Active Pharmaceutical Ingredients Market – Regional Analysis
    • 7.1. Overview
      • 7.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 7.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 7.2. North America
      • 7.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.2.2. North America Market Revenue, By Synthesis, 2016 – 2028
      • 7.2.3. North America Market Revenue, By Manufacturing Type, 2016 – 2028
      • 7.2.4. North America Market Revenue, By API Type, 2016 – 2028
      • 7.2.4. North America Market Revenue, By Drug Type, 2016 – 2028
      • 7.2.4. North America Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.2.5. U.S.
        • 7.2.5.1. U.S. Market Revenue, By Synthesis, 2016 – 2028
        • 7.2.5.2. U.S. Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.2.5.3. U.S. Market Revenue, By API Type, 2016 – 2028
        • 7.2.5.3. U.S. Market Revenue, By Drug Type, 2016 – 2028
        • 7.2.5.3. U.S. Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.2.6. Canada
        • 7.2.6.1. Canada Market Revenue, By Synthesis, 2016 – 2028
        • 7.2.6.2. Canada Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.2.6.3. Canada Market Revenue, By API Type, 2016 – 2028
        • 7.2.6.3. Canada Market Revenue, By Drug Type, 2016 – 2028
        • 7.2.6.3. Canada Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.2.7. Mexico
        • 7.2.7.1. Mexico Market Revenue, By Synthesis, 2016 – 2028
        • 7.2.7.2. Mexico Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.2.7.3. Mexico Market Revenue, By API Type, 2016 – 2028
    • 7.3. Europe
      • 7.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.3.2. Europe Market Revenue, By Synthesis, 2016 – 2028
      • 7.3.3. Europe Market Revenue, By Manufacturing Type, 2016 – 2028
      • 7.3.4. Europe Market Revenue, By API Type, 2016 – 2028
      • 7.3.4. Europe Market Revenue, By Drug Type, 2016 – 2028
      • 7.3.4. Europe Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.3.5. Germany
        • 7.3.5.1. Germany Market Revenue, By Synthesis, 2016 – 2028
        • 7.3.5.2. Germany Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.3.5.3. Germany Market Revenue, By API Type, 2016 – 2028
        • 7.3.5.3. Germany Market Revenue, By Drug Type, 2016 – 2028
        • 7.3.5.3. Germany Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.3.6. France
        • 7.3.6.1. France Market Revenue, By Synthesis, 2016 – 2028
        • 7.3.6.2. France Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.3.6.3. France Market Revenue, By API Type, 2016 – 2028
        • 7.3.6.3. France Market Revenue, By Drug Type, 2016 – 2028
        • 7.3.6.3. France Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.3.7. U.K.
        • 7.3.7.1. U.K. Market Revenue, By Synthesis, 2016 – 2028
        • 7.3.7.2. U.K. Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.3.7.3. U.K. Market Revenue, By API Type, 2016 – 2028
        • 7.3.7.3. U.K. Market Revenue, By Drug Type, 2016 – 2028
        • 7.3.7.3. U.K. Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.3.8. Italy
        • 7.3.8.1. Italy Market Revenue, By Synthesis, 2016 – 2028
        • 7.3.8.2. Italy Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.3.8.3. Italy Market Revenue, By API Type, 2016 – 2028
        • 7.3.8.3. Italy Market Revenue, By Drug Type, 2016 – 2028
        • 7.3.8.3. Italy Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.3.9. Spain
        • 7.3.9.1. Spain Market Revenue, By Synthesis, 2016 – 2028
        • 7.3.9.2. Spain Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.3.9.3. Spain Market Revenue, By API Type, 2016 – 2028
        • 7.3.9.3. Spain Market Revenue, By Drug Type, 2016 – 2028
        • 7.3.9.3. Spain Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.3.10. Rest of Europe
        • 7.3.10.1. Rest of Europe Market Revenue, By Synthesis, 2016 – 2028
        • 7.3.10.2. Rest of Europe Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.3.10.3. Rest of Europe Market Revenue, By API Type, 2016 – 2028
        • 7.3.10.3. Rest of Europe Market Revenue, By Drug Type, 2016 – 2028
        • 7.3.10.3. Rest of Europe Market Revenue, By Therapeutic Application, 2016 – 2028
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.4.2. Asia Pacific Market Revenue, By Synthesis, 2016 – 2028
      • 7.4.3. Asia Pacific Market Revenue, By Manufacturing Type, 2016 – 2028
      • 7.4.4. Asia Pacific Market Revenue, By API Type, 2016 – 2028
      • 7.4.4. Asia Pacific Market Revenue, By Drug Type, 2016 – 2028
      • 7.4.4. Asia Pacific Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.4.5. China
        • 7.4.5.1. China Market Revenue, By Synthesis, 2016 – 2028
        • 7.4.5.2. China Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.4.5.3. China Market Revenue, By API Type, 2016 – 2028
        • 7.4.5.3. China Market Revenue, By Drug Type, 2016 – 2028
        • 7.4.5.3. China Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.4.6. Japan
        • 7.4.6.1. Japan Market Revenue, By Synthesis, 2016 – 2028
        • 7.4.6.2. Japan Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.4.6.3. Japan Market Revenue, By API Type, 2016 – 2028
        • 7.4.6.3. Japan Market Revenue, By Drug Type, 2016 – 2028
        • 7.4.6.3. Japan Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.4.7. India
        • 7.4.7.1. India Market Revenue, By Synthesis, 2016 – 2028
        • 7.4.7.2. India Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.4.7.3. India Market Revenue, By API Type, 2016 – 2028
        • 7.4.7.3. India Market Revenue, By Drug Type, 2016 – 2028
        • 7.4.7.3. India Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.4.8. South Korea
        • 7.4.8.1. South Korea Market Revenue, By Synthesis, 2016 – 2028
        • 7.4.8.2. South Korea Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.4.8.3. South Korea Market Revenue, By API Type, 2016 – 2028
        • 7.4.8.3. South Korea Market Revenue, By Drug Type, 2016 – 2028
        • 7.4.8.3. South Korea Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.4.9. South-East Asia
        • 7.4.9.1. South-East Asia Market Revenue, By Synthesis, 2016 – 2028
        • 7.4.9.2. South-East Asia Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.4.9.3. South-East Asia Market Revenue, By API Type, 2016 – 2028
        • 7.4.9.3. South-East Asia Market Revenue, By Drug Type, 2016 – 2028
        • 7.4.9.3. South-East Asia Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.4.10. Rest of Asia Pacific
        • 7.4.10.1. Rest of Asia Pacific Market Revenue, By Synthesis, 2016 – 2028
        • 7.4.10.2. Rest of Asia Pacific Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.4.10.3. Rest of Asia Pacific Market Revenue, By API Type, 2016 – 2028
        • 7.4.10.3. Rest of Asia Pacific Market Revenue, By Drug Type, 2016 – 2028
        • 7.4.10.3. Rest of Asia Pacific Market Revenue, By Therapeutic Application, 2016 – 2028
    • 7.5. Latin America
      • 7.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.5.2. Latin America Market Revenue, By Synthesis, 2016 – 2028
      • 7.5.3. Latin America Market Revenue, By Manufacturing Type, 2016 – 2028
      • 7.5.4. Latin America Market Revenue, By API Type, 2016 – 2028
      • 7.5.4. Latin America Market Revenue, By Drug Type, 2016 – 2028
      • 7.5.4. Latin America Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.5.5. Brazil
        • 7.5.5.1. Brazil Market Revenue, By Synthesis, 2016 – 2028
        • 7.5.5.2. Brazil Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.5.5.3. Brazil Market Revenue, By API Type, 2016 – 2028
        • 7.5.5.3. Brazil Market Revenue, By Drug Type, 2016 – 2028
        • 7.5.5.3. Brazil Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.5.6. Argentina
        • 7.5.6.1. Argentina Market Revenue, By Synthesis, 2016 – 2028
        • 7.5.6.2. Argentina Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.5.6.3. Argentina Market Revenue, By API Type, 2016 – 2028
        • 7.5.6.3. Argentina Market Revenue, By Drug Type, 2016 – 2028
        • 7.5.6.3. Argentina Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.5.7. Rest of Latin America
        • 7.5.7.1. Rest of Latin America Market Revenue, By Synthesis, 2016 – 2028
        • 7.5.7.2. Rest of Latin America Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.5.7.3. Rest of Latin America Market Revenue, By API Type, 2016 – 2028
        • 7.5.7.3. Rest of Latin America Market Revenue, By Drug Type, 2016 – 2028
        • 7.5.7.3. Rest of Latin America Market Revenue, By Therapeutic Application, 2016 – 2028
    • 7.6. The Middle-East and Africa
      • 7.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 7.6.2. The Middle-East and Africa Market Revenue, By Synthesis, 2016 – 2028
      • 7.6.3. The Middle-East and Africa Market Revenue, By Manufacturing Type, 2016 – 2028
      • 7.6.4. The Middle-East and Africa Market Revenue, By API Type, 2016 – 2028
      • 7.6.4. The Middle-East and Africa Market Revenue, By Drug Type, 2016 – 2028
      • 7.6.4. The Middle-East and Africa Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.6.5. GCC Countries
        • 7.6.5.1. GCC Countries Market Revenue, By Synthesis, 2016 – 2028
        • 7.6.5.2. GCC Countries Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.6.5.3. GCC Countries Market Revenue, By API Type, 2016 – 2028
        • 7.6.5.3. GCC Countries Market Revenue, By Drug Type, 2016 – 2028
        • 7.6.5.3. GCC Countries Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.6.6. South Africa
        • 7.6.6.1. South Africa Market Revenue, By Synthesis, 2016 – 2028
        • 7.6.6.2. South Africa Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.6.6.3. South Africa Market Revenue, By API Type, 2016 – 2028
        • 7.6.6.3. South Africa Market Revenue, By Drug Type, 2016 – 2028
        • 7.6.6.3. South Africa Market Revenue, By Therapeutic Application, 2016 – 2028
      • 7.6.7. Rest of Middle-East Africa
        • 7.6.7.1. Rest of Middle-East Africa Market Revenue, By Synthesis, 2016 – 2028
        • 7.6.7.2. Rest of Middle-East Africa Market Revenue, By Manufacturing Type, 2016 – 2028
        • 7.6.7.3. Rest of Middle-East Africa Market Revenue, By API Type, 2016 – 2028
        • 7.6.7.3. Rest of Middle-East Africa Market Revenue, By Drug Type, 2016 – 2028
        • 7.6.7.3. Rest of Middle-East Africa Market Revenue, By Therapeutic Application, 2016 – 2028
  • Chapter No. 8 Active Pharmaceutical Ingredients Market – Industry Analysis
    • 8.1. Introduction
    • 8.2. Market Drivers
      • 8.2.1. Driving Factor 1 Analysis
      • 8.2.2. Driving Factor 2 Analysis
    • 8.3. Market Restraints
      • 8.3.1. Restraining Factor Analysis
    • 8.4. Market Opportunities
      • 8.4.1. Market Opportunity Analysis
    • 8.5. Porter’s Five Forces Analysis
    • 8.6. PEST Analysis
    • 8.7. Regulatory Landscape
    • 8.8. Technulogy Landscape
    • 8.9. Regional Market Trends
      • 8.9.1. North America
      • 8.9.2. Europe
      • 8.9.3. Asia Pacific
      • 8.9.4. Latin America
      • 8.9.5. The Middle-East and Africa
    • 8.10. Pricing Analysis
    • 8.11. Value Chain Analysis
    • 8.12. Downstream Buyers
    • 8.13. Distributors/Traders List
  • Chapter No. 9 Competitive Landscape
    • 9.1. Company Market Share Analysis – 2019
      • 9.1.1. Global Active Pharmaceutical Ingredients Market: Company Market Share, 2019
      • 9.1.2. Global Active Pharmaceutical Ingredients Market, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 9.1.3. Global Active Pharmaceutical Ingredients Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 9.1.4. Global Active Pharmaceutical Ingredients Market: Radar Determinant Chart, 2019
    • 9.2. Strategic Developments
      • 9.2.1. Acquisitions & Mergers
      • 9.2.2. New Product Launch
      • 9.2.3. Regional Expansion
    • 9.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 10 Company Profiles
    • 10.1. Merck & Co., Inc.
      • 10.1.1. Company Overview
      • 10.1.2. Key Executives
      • 10.1.3. Product Portfulio
      • 10.1.4. Financial Overview
      • 10.1.5. Operating Business Segments
      • 10.1.6. Business Performance
      • 10.1.7. Recent Developments
    • 10.2. AbbVie, Inc.
    • 10.3. Bristul-Myers Squibb Company
    • 10.4. Cipla, Inc.
    • 10.5. Teva Pharmaceutical Industries Ltd.
    • 10.6. Aurobindo Pharma
    • 10.7. Viatris Inc.
    • 10.8. Boehringer Ingelheim International GmbH
  • Chapter No. 11 Marketing Strategy Analysis
    • 11.1. Marketing Channel
    • 11.2. Direct Marketing
    • 11.3. Indirect Marketing
    • 11.4. Marketing Channel Development Trends
    • 11.5. Economic/Pulitical Environmental Change
  • Chapter No. 12 Research Methodulogy
    • 12.1. Research Methodulogy
    • 12.2. Phase I - Secondary Research
    • 12.3. Phase II - Data Modeling
      • 12.3.1. Company Share Analysis Model
      • 12.3.2. Revenue Based Modeling
    • 12.4. Phase III - Primary Research
    • 12.5. Research Limitations
      • 12.5.1. Assumptions

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Active Pharmaceutical Ingredients market. Zion Research has collected and analyzed key data belong to the global Active Pharmaceutical Ingredients market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Active Pharmaceutical Ingredients across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Active Pharmaceutical Ingredients industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Active Pharmaceutical Ingredients market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Active pharmaceutical ingredient (API) is used in the manufacturing of a pharmaceutical drug as a biologically active compound. API is an organic compound which has unique chemical structure and stereochemistry. Any medication is made up of two portions. The first is the active pharmaceutical ingredients, which is the essential element of the drug. The second is known as an excipient which is an inner part of the drug. The active pharmaceutical ingredient is the chemically active substance, which is intended to deliver the desirable impact in the body.

The market for API is driven by a number of factors, such as increasing prevalence of chronic diseases, technological advancements in the API manufacturing, and growing incidences of age-related diseases. Furthermore, patent expiration of major drugs that increased generic drug sales, government initiatives flourishing the market growth. However, stringent regulatory requirement and decline in global economics may curb the worldwide active pharmaceutical ingredient market.

Global Active Pharmaceutical Ingredients market

The global active pharmaceutical ingredient market is broadly segmented based on API synthesis, type of manufacturing, type of API, and type of drug, application and by region. On the basis of API, synthesis market is segmented into biotech API, synthetic chemical API, and HPAPI (Highly Potent Active Pharmaceutical Ingredient). The biotech API is the leading segment and acquired a significant share in overall API market in 2015. On the basis of the type of manufacturing, the market is segmented into API contract manufacturing and in-house API manufacturing. The contract manufacturing emerged as major segment due to lower cost and higher quality of production of the API. Type segment of API includes synthetic API and biological API.

By type of drug, the market is segmented into branded drugs, generic drugs, and OTC (Over the Counter) drugs.  The generic prescription drugs segment is expected to witness the highest growth in the upcoming years due to their low cost compared to branded drugs. Cardiology, oncology, anti-inflammatory, gastrointestinal and others are the key therapeutic application segmentation of API market. According to World Health Organization (WHO), cancer was one of the major causes of mortality across the globe. Thus, the oncology segment is expected to be the fastest-growing segment of the global API market.

North America dominated the global API market in 2015 followed by Europe due to development in the pharmaceutical industry, and technological advancement in API. Asia-Pacific is considered as a fastest growing market for active pharmaceutical ingredient due to increasing new drug application in this region.

Major players in active pharmaceutical ingredient market are Sun Pharmaceuticals Industries Limited, Novartis International AG, BASF SE, Pfizer, Inc., Aurobindo, Albemarle Corporation, and Boehringer Ingelheim among others.


Frequently Asked Questions

The global Active Pharmaceutical Ingredients market was valued at USD 202.90 Billion in 2020.

The global Active Pharmaceutical Ingredients market is expected to reach USD 101.48 Billion by 2028, growing at a CAGR of 5.1% between 2021 to 2028.

Some of the factors driving the growth of active pharmaceutical ingredients market is the increasing prevalence of chronic disorders care and support, older population, high investment in the department of research and development, increased spending on the healthcare, growing incidence of COVID-19 cases, and the inevitable technological advancements. In the recent past, the incidence of chronic diseases such as diabetes, coronary artery disease, chronic obstructive pulmonary disease (COPD), asthma, hepatitis, arthritis, and cancer has increased significantly in major regions across the globe. This can be attributed to the rising geriatric population across the globe, changing lifestyles, and dietary changes as a result of rapid urbanization.

Geographically, the active pharmaceutical ingredients market is segmented into North America, Europe, Asia, and Rest of the World. In recent times, North America accounted for the largest share of the active pharmaceutical ingredients market, followed by Europe and the Asia Pacific. The reason for North America’s dominance in the global market is attributed to the rising incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for specialty drugs, and technological advancements in the manufacturing processes of APIs.

Some of the leading players in the market are Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Cipla, Inc., Teva Pharmaceutical Industries Ltd., Albemarle Corporation, Viatris Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social